Vaccine production, distribution, access, and uptake
- PMID: 21664680
- PMCID: PMC3164579
- DOI: 10.1016/S0140-6736(11)60478-9
Vaccine production, distribution, access, and uptake
Abstract
For human vaccines to be available on a global scale, complex production methods, meticulous quality control, and reliable distribution channels are needed to ensure that the products are potent and effective at the point of use. The technologies used to manufacture different types of vaccines can strongly affect vaccine cost, ease of industrial scale-up, stability, and, ultimately, worldwide availability. The complexity of manufacturing is compounded by the need for different formulations in different countries and age-groups. Reliable vaccine production in appropriate quantities and at affordable prices is the cornerstone of developing global vaccination policies. However, to ensure optimum access and uptake, strong partnerships are needed between private manufacturers, regulatory authorities, and national and international public health services. For vaccines whose supply is insufficient to meet demand, prioritisation of target groups can increase the effect of these vaccines. In this report, we draw from our experience of vaccine development and focus on influenza vaccines as an example to consider production, distribution, access, and other factors that affect vaccine uptake and population-level effectiveness.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Comment in
-
Will the Decade of Vaccines mean business as usual?Lancet. 2011 Jul 30;378(9789):382-5. doi: 10.1016/S0140-6736(11)60710-1. Epub 2011 Jun 12. Lancet. 2011. PMID: 21664683 No abstract available.
-
Public-private collaboration in vaccine research.Lancet. 2011 Jul 30;378(9789):385-6. doi: 10.1016/S0140-6736(11)60690-9. Epub 2011 Jun 12. Lancet. 2011. PMID: 21664686 No abstract available.
References
-
- Modlin JF. The bumpy road to polio eradication. N Engl J Med. 362:2346–9. - PubMed
-
- American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362–6. - PubMed
-
- Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907–13. - PubMed
-
- McNeil C. Who invented the VLP cervical cancer vaccines? J Natl Cancer Inst. 2006;98:433. - PubMed
-
- Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555–63. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
